☆ 4.2 Article

Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient

ACTA HAEMATOLOGICA (2023)

Related references

Note: Only part of the references are listed.

Article Pathology

Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study

Derya Demir et al.

Summary: Myeloid sarcoma (MS) is a rare tumor that occurs outside the bone marrow. This study investigated the clinicopathological, phenotypic, molecular, and prognostic features of 45 MS patients and found that increasing age is associated with a worse outcome.

JOURNAL OF CLINICAL PATHOLOGY (2023)

Add to Collection

Review Oncology

NPM 1 Mutations in AML-The Landscape in 2023

Naman Sharma et al.

Summary: The NPM1 gene mutation is found in approximately one-third of newly diagnosed acute myeloid leukemia (AML) cases. It has been reclassified as a distinct entity in the recent AML classification and carries important diagnostic, clinical, and prognostic implications. This review aims to summarize the pathophysiology, diagnostic and prognostic challenges, and treatment strategies, including the use of novel targeted therapies, for NPM1-mutated AML.

CANCERS (2023)

Add to Collection

Article Oncology

Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine

Keith W. Pratz et al.

Summary: This study explored the outcomes of patients with acute myeloid leukemia treated with venetoclax and azacitidine who achieved composite complete remission (CRc) and measurable residual disease (MRD) < 10(-3). The results showed that patients who achieved CRc and MRD < 10(-3) had longer duration of remission, event-free survival, and overall survival compared to those with MRD >= 10(-3).

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia

Li-xia Zhu et al.

Summary: The study aimed to investigate the incidence, sites, main pathogens, and risk factors for infectious complications in adult acute myeloid leukemia (AML) patients receiving venetoclax combined with decitabine or azacitidine. The results showed that compared to conventional chemotherapy, venetoclax combined with decitabine or azacitidine significantly reduced the incidence of infectious complications. High leukemia burden and fever were identified as independent risk factors for infections.

SUPPORTIVE CARE IN CANCER (2022)

Add to Collection

Article Oncology

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations

Somedeb Ball et al.

Summary: The study revealed frequent targetable mutations in EM-AML patients, with EM-site NGS being recommended for selecting potential targeted therapies for these patients. Targetable alterations such as IDH1, NPM1, IDH2, FLT3, and KMT2A-PTD were identified in a significant proportion of patients, and treatment with IDH inhibitors based on EM-site NGS showed promising results in achieving complete responses.

CANCER (2022)

Add to Collection

Review Hematology

Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved

Rory M. Shallis et al.

Summary: The classification and definition of myeloid sarcoma by the World Health Organization is imprecise, with a more accurate term being extramedullary acute myeloid leukemia tumor (eAML). eAML is associated with aberration of cellular adhesion molecules, chemokine receptors/ligands, and RAS-MAPK/ERK signaling. Diagnosis requires tissue biopsy, and treatment may involve both local therapy and systemic anti-leukemia therapy.

BLOOD REVIEWS (2021)

Add to Collection

Review Allergy

Leukaemia cutis for clinicians, a literature review

Malgorzata Osmola et al.

Summary: Leukaemia cutis involves infiltration of the skin by leukaemia cells, presenting with a wide range of clinical manifestations that can be difficult to distinguish from other skin changes. Skin biopsy is crucial for diagnosis in some cases, and this review discusses the most frequently represented types of leukaemia in leukaemia cutis, as well as skin changes in multiple myeloma, focusing on clinical presentation of LC and patient prognosis.

POSTEPY DERMATOLOGII I ALERGOLOGII (2021)

Add to Collection

Article Hematology

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

C. D. DiNardo et al.

BLOOD (2020)

Add to Collection

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

A Rare Case of Leukemia Cutis as the First Presentation of a Myelodysplastic Syndrome to Acute Myeloid Leukemia Transformation

Dawood Findakly et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2020)

Add to Collection

Review Medicine, General & Internal

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome A case report and literature review

Takayuki Katagiri et al.

MEDICINE (2017)

Add to Collection

Letter Oncology

Gingival myeloid sarcoma in myelodysplastic syndrome

Pasquale Niscola et al.

SUPPORTIVE CARE IN CANCER (2013)

Add to Collection

Article Geriatrics & Gerontology

Managing myelodysplastic syndromes in very old patients: a teaching case report

Pasquale Niscola et al.

CLINICAL INTERVENTIONS IN AGING (2013)

Add to Collection

Article Hematology

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg et al.

BLOOD (2012)

Add to Collection

Letter Oncology

Multicentric myeloid/NK sarcoma in an aleukemic patient evolved in refractory acute leukemia

Laura Scaramucci et al.

LEUKEMIA RESEARCH (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.